Cargando…

PI-04: OXYGEN GRADIENT EKTACYTOMETRY-DERIVED BIOMARKERS ARE ASSOCIATED WITH THE OCCURRENCE OF ACUTE COMPLICATIONS IN SICKLE CELL DISEASE

Detalles Bibliográficos
Autores principales:	M., RAB, C., KANNE, C., BOISSON, J., BOS, B., VAN OIRSCHOT, M., HOUWING, C., RENOUX, R., SCHUTGENS, M., BARTELS, A., RIJNEVELD, E., NUR, M., CNOSSEN, J., PHILIPPE, R., FORT, P., CONNES, R., VAN WIJK, V., SHEEHAN, E., VAN BEERS
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Pitch Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426792/ http://dx.doi.org/10.1097/01.HS9.0000872876.53698.69

Ejemplares similares

PI-02: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: M., VAN DIJK, et al.
Publicado: (2022)

Oxygen gradient ektacytometry‐derived biomarkers are associated with vaso‐occlusive crises and correlate with treatment response in sickle cell disease
por: Rab, Minke A. E., et al.
Publicado: (2020)

PI-05: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS
por: M., RAB, et al.
Publicado: (2022)

Comment on: Oxygen gradient ektacytometry does not predict pain in children with sickle cell anaemia
por: Sheehan, Vivien A., et al.
Publicado: (2022)

Methodological aspects of the oxygenscan in sickle cell disease: A need for standardization
por: Rab, Minke A.E., et al.
Publicado: (2019)

Ektacytometry Analysis of Post-splenectomy Red Blood Cell Properties Identifies Cell Membrane Stability Test as a Novel Biomarker of Membrane Health in Hereditary Spherocytosis
por: Berrevoets, M. C., et al.
Publicado: (2021)

PI-08: HIGH DISEASE BURDEN, MORBIDITY AND MORTALITY AMONG CHILDREN WITH SICKLE CELL ANAEMIA IN UGANDA
por: R., NAMAZZI, et al.
Publicado: (2022)

PI-03: THE EFFECT OF HYDROXYUREA IN THE GUT MICROBIOME OF ANGOLAN CHILDREN WITH SICKLE CELL DISEASE
por: M., DELGADINHO, et al.
Publicado: (2022)

P1424: ONE-YEAR FOLLOW-UP OF A PHASE 2 STUDY OF MITAPIVAT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR THE TREATMENT OF SICKLE CELL DISEASE
por: van Dijk, Myrthe, et al.
Publicado: (2023)

PI-06: THE NURSE CHAMPION MODEL FOR NEWBORN SCREENING FOR SICKLE CELL DISEASE IN SUB-SAHARAN AFRICA: AN IMPLEMENTATION SCIENCE PROTOCOL
por: C., JAJA, et al.
Publicado: (2022)

P1501: FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: van Dijk, M. J., et al.
Publicado: (2022)

PI-11: EXTREME VARIABILITY OF THE PROGNOSTIC VALUE OF BIOLOGICAL PARAMETERS ACCORDING TO STATISTICAL METHODOLOGY IN PEDIATRIC SICKLE CELL DISEASE COHORT STUDIES
por: J., SOMMET, et al.
Publicado: (2022)

PI-07: THE INTERNATIONAL HEMOGLOBINOPATHY RESEARCH NETWORK (INHERENT): AN INTERNATIONAL INITIATVE TO STUDY THE ROLE OF GENETIC MODIFIERS IN HEMOGLOBINOPATHIES
por: P., KOUNTOURIS, et al.
Publicado: (2022)

Shear-Stress-Gradient and Oxygen-Gradient Ektacytometry in Sickle Cell Patients at Steady State and during Vaso-Occlusive Crises
por: Boisson, Camille, et al.
Publicado: (2022)

5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE
por: van Dijk, M.J., et al.
Publicado: (2023)

PI-10: DIETARY IRON RESTRICTION PROTECTS AGAINST VASO-OCCLUSION AND ORGAN DAMAGE IN SICKLE CELL DISEASE
por: H., LI, et al.
Publicado: (2022)

P-014: USE OF OXYGEN GRADIENT EKTACYTOMETRY TO MEASURE EFFICACY IN CELL-BASED THERAPIES
por: C., KANNE, et al.
Publicado: (2022)

The pitching edge video
Publicado: (1994)

PI-09: LESSONS LEARNED FROM ONE DECADE EXPERIENCE OF THE « CENTRE DE RECHERCHE ET DE LUTTE CONTRE LA DRÉPANOCYTOSE (CRLD) » IN BAMAKO, MALI.
por: D., DIALLO, et al.
Publicado: (2022)

PI-01: GRNDAD AND COUSIN: INVESTIGATOR-INITIATED COLLABORATIONS TO IMPROVE CARE IN SICKLE CELL DISEASE
por: J., LITTLE, et al.
Publicado: (2022)

Effects of Genotypes and Treatment on Oxygenscan Parameters in Sickle Cell Disease
por: Boisson, Camille, et al.
Publicado: (2021)

Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients
por: Rab, Minke A.E., et al.
Publicado: (2019)

P1492: PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS
por: Rab, M., et al.
Publicado: (2022)

P1566: PROTON PUMP INHIBITION FOR SECONDARY HEMOCHROMATOSIS IN HEREDITARY ANEMIA, A PHASE III PLACEBO-CONTROLLED RANDOMIZED CROSS-OVER CLINICAL TRIAL
por: Van Vuren, A., et al.
Publicado: (2022)

P-029: OCCLUSIONCHIP: A FUNCTIONAL MICROCAPILLARY OCCLUSION ASSAY COMPLEMENTARY TO EKTACYTOMETRY FOR ASSESSING RED CELL HEALTH IN SICKLE CELL DISEASE
por: Y., MAN, et al.
Publicado: (2022)

Oxygen gradient ektacytometry does not predict pain in children with sickle cell anaemia
por: Nardo-Marino, Amina, et al.
Publicado: (2022)

P1481: SYSTEMATICALLY REDUCED RED CELL PHOSPHATIDYLSERINE FLIPPASE ACTIVITY IS SUFFICIENT TO INDUCE HEREDITARY HEMOLYTIC ANEMIA
por: van Dijk, Myrthe, et al.
Publicado: (2023)

Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia
por: Sadaf, Alina, et al.
Publicado: (2021)

PB2509: RED BLOOD CELL PYRUVATE KINASE PROPERTIES IN SICKLE CELL DISEASE – OF MICE AND MEN
por: Traets, Marissa, et al.
Publicado: (2023)

P1550: NEW GENERATION EKTACYTOMETRY STUDY OF RED BLOOD CELLS RHEOLOGICAL PARAMETERS IN HEMOGLOBINOPATHIES
por: Krishnevskaya, E., et al.
Publicado: (2022)

Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo‐controlled randomized cross‐over clinical trial
por: van Vuren, Annelies, et al.
Publicado: (2022)

P1500: 2,3-DIPHOSPHOGLYCERATE DETECTION VIA DIRECT INFUSION HIGH RESOLUTION MASS SPECTROMETRY CORRELATES WITH QUANTITATIVE DETECTION IN BLOOD OF PATIENTS WITH SICKLE CELL DISEASE
por: van der Veen, S., et al.
Publicado: (2022)

P-023: 2,3-DIPHOSPHOGLYCERATE DETECTION VIA DIRECT INFUSION HIGH RESOLUTION MASS SPECTROMETRY CORRELATES WITH QUANTITATIVE DETECTION IN BLOOD OF PATIENTS WITH SICKLE CELL DISEASE
por: S., VAN DER VEEN, et al.
Publicado: (2022)

OcclusionChip: A functional microcapillary occlusion assay complementary to ektacytometry for detection of small-fraction red blood cells with abnormal deformability
por: Man, Yuncheng, et al.
Publicado: (2022)

Donor Age and Red Cell Age Contribute to the Variance in Lorrca Indices in Healthy Donors for Next Generation Ektacytometry: A Pilot Study
por: van Cromvoirt, Ankie M., et al.
Publicado: (2021)

AG-348 (mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and adenosine triphosphate levels over a broad range of PKLR genotypes
por: Rab, Minke A.E., et al.
Publicado: (2020)

P1065: CONGENITAL ERYTHROCYTOSIS DUE TO HETEROZYGOUS VARIANTS IN THE BISPHOSPHOGLYCERATE MUTASE GENE
por: van Dijk, M. J., et al.
Publicado: (2022)

P717: AG946, A PYRUVATE KINASE (PK) ACTIVATOR IMPROVES PK PROPERTIES AND RED BLOOD CELL (RBC) METABOLISM UPON EX VIVO TREATMENT OF RBCS FROM PATIENTS WITH MYELODYSPLASTIC SYNDROMES
por: de Wilde, Jonathan, et al.
Publicado: (2023)

Metabolic Fingerprint in Hereditary Spherocytosis Correlates With Red Blood Cell Characteristics and Clinical Severity
por: van Dooijeweert, Birgit, et al.
Publicado: (2021)

Microfluidic capillary networks are more sensitive than ektacytometry to the decline of red blood cell deformability induced by storage
por: Piety, Nathaniel Z., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iieshje7gtvq0nkj96ls9aqpv5